Company intelligence / Profile preview
Eupraxia Pharmaceuticals Inc.
Victoria, British Columbia, Canadaeupraxiapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase 2b clinical trial (SPRINGBOARD) for EP-104IAR for knee osteoarthritis pain, which met its primary endpoint and three of four secondary endpoints. Currently conducting Phase 1b/2a RESOLVE trial for EP-104GI for eosinophilic esophagitis with positive data from the first six cohorts showing improvements in tissue health and symptom reduction[3][5][6].
- Therapeutic areas
- GastroenterologyOncologyRheumatology
- Modalities
- Extended-release drug formulations
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Eupraxia Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eupraxia Pharmaceuticals Inc..